Jacobs Levy Equity Management’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Jacobs Levy Equity Management’s Portfolio FRTX Stock Details FRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-151	Closed	-$144K	–	1078
2016 Q3	$144K	Hold	151	–	–	﹤0.01%	940
2016 Q2	$215K	Hold	151	–	–	﹤0.01%	993
2016 Q1	$185K	Sell	151 -33	-18%	-$38.1K	﹤0.01%	980
2015 Q4	$238K	Sell	184 -4	-2%	-$5.22K	﹤0.01%	682
2015 Q3	$272K	Buy	188 +39	+26%	+$75.3K	0.01%	672
2015 Q2	$329K	Buy	149 +8	+6%	+$25.1K	0.01%	633
2015 Q1	$419K	Buy	141 +36	+34%	+$115K	0.01%	599
2014 Q4	$346K	Buy	105 +84	+400%	+$297K	0.01%	659
2014 Q3	$73K	Sell	21 -59	-74%	-$229K	﹤0.01%	793
2014 Q2	$308K	Buy	80 +20	+33%	+$75.3K	0.01%	708
2014 Q1	$244K	Buy	+60	New	+$268K	﹤0.01%	785

Other funds holding FRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jacobs Levy Equity Management's FRTX Position: Q4 2016 in Review

Jacobs Levy Equity Management sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q4 2016, closing a stake of 151 shares — an estimated $144K sold.

Jacobs Levy Equity Management first reported a position in FRTX in Q1 2014 and held it in 11 quarters. The position peaked at $419K in Q1 2015. 26 funds tracked by Wall St. Rank hold FRTX as of Q4 2016.

Jacobs Levy Equity Management reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
Jacobs Levy Equity Management sold 151 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $144K.
Jacobs Levy Equity Management first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q1 2014 and held it in 11 quarters.
Jacobs Levy Equity Management's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $419K in Q1 2015.
26 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q4 2016.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2016, filed 14 Feb 2017.